Aspirin for Secondary Prevention: Are Patients Getting Wiser Than Their Physicians?

2 , 3 , 4 , 5 The largest long-term trial of aspirin after myocardial infarction, the Aspirin Myocardial Infarction Study ( Figure 1 ), showed a trend to harm (increased mortality) rather than benefit, 5 the authors concluding: “aspirin is not recommended for routine use in patients who have survived a myocardial infarction.” The PARIS-II (Persantine-Aspirin Reinfarction Study Part II) was the second largest, long-term, placebo-controlled trial of an antiplatelet regimen after myocardial infarction ( Figure 1 ).

also in 53,322 other papers